21 November 2023 | Tuesday | News
Image Source : Public Domain
Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, and Trajan Scientific and Medical, creator of Neoteryx Mitra® biological sample collection devices based on VAMS® technology, announce a partnership to collaborate on microsampling solutions for metabolomics research.
Life science research studies are frequently constrained by their inability to easily and efficiently secure adequate, stable biological samples. Mitra devices offer precision via a volumetric absorptive microsampling method that is minimally invasive and user-friendly. This microsampling technique is ideal when working in a preclinical research lab setting. Smaller microliter sample volumes also enable research not possible with standard blood collection techniques, such as sample collection at athletic events, in-home or home-bound settings, when working with vulnerable populations, and at remote field research locations.
"This democratizes the ability to collect sufficient, stable blood samples for metabolomic analysis. Our work with Trajan will help researchers access patients more easily through decentralized trials and foster greater adoption of metabolomics," said Rangaprasad (Ranga) Sarangarajan, Ph.D., Chief Scientific Officer at Metabolon. "Advanced metabolomic analytical techniques can now be applied to a much broader array of academic and commercial life science research."
"Through this partnership, we are breaking down the traditional sample collection barriers in metabolomic analysis, enabling researchers to access a broader and more diverse spectrum of patients and clinical trial or research participants," said Cathy Cordova, Vice President of Clinical Solutions at Trajan. "Our collaboration with Metabolon marks a significant stride towards a more comprehensive understanding of human health and disease development by eliminating reliance on clinic-based specimen collection to collecting a reliable sample for use in Metabolon's targeted and untargeted panels."